Watson and Takeda resolve Actos litigation
UNITED STATES – US generic drugs company Watson Pharmaceuticals has settled its patent litigation with the Japanese firm Takeda Pharmaceuticals
over, Takeda’s diabetes drug Actos (pioglitazone). Under the terms of the agreement, Takeda has granted Watson a non-exclusive,
royalty-free licence to its patents covering pioglitazone. Watson will be able to launch a generic version of the drug in
August 2012. The patents covering the drug expire in 2016, according to the Food and Drug Administration.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.